Advancing Climate Action, Governance Excellence, and Global Scientific ImpactPISCATAWAY, N.J., April 14, 2026 /PRNewswire/ — GenScript Biotech Corporation today announced its 2025 Environmental, Social, and Governance (ESG) Report, positioning the company at the forefront of responsible innovation in biotechnology and reinforcing its role as a trusted global partner powering the future of healthcare, science, and sustainability.
At a time when biotech is increasingly central to global health, and climate resilience, GenScript’s ESG Report demonstrates how the company is embedding sustainability, governance, and societal impact into its growth strategy – not as an obligation, but as a competitive advantage.”Sustainability is not adjacent to our strategy; it is embedded within it,” said Sherry Shao, Rotating CEO of GenScript. “In 2025, we strengthened governance, accelerated climate action, advanced responsible supply chains, and continued building a diverse, high-performing global organization. As biotechnology reshapes the future, we are committed to doing so responsibly – creating long-term value for society, our partners, and our stakeholders.”FROM FRAMEWORK TO FORCE: ESG AS A STRATEGIC GROWTH ENGINEGenScript’s 2025 ESG Report moves beyond reporting, to demonstrate a system-level execution – structured around five core pillars – governance, workforce, environment, supply chain, and community – operating as integrated drivers of long-term value creation.The company’s ESG strategy is aligned with its mission ‘to make people and nature healthier through biotechnology’ and reflects a data-driven, globally consistent, and operationally embedded approach to sustainability.2025 ESG HIGHLIGHTS1) Governance That Scales with Global ImpactBoard-level oversight through the Risk Management and ESG Committee ensures enterprise-wide accountability and resilience100% coverage of employee ethics training and conflict-of-interest evaluations reinforces integrity at scaleGlobally unified governance aligned with leading regulatory and compliance standards2) Responsible Supply Chain Management Enabling Customers WorldwideActive Supplier Partner of the Pharmaceutical Supply Chain Initiative100% of targeted suppliers aligned with GenScript’s Supplier Code of ConductESG audits, risk mitigation, and Supplier Day engagement driving resilient, transparent supply ecosystems3) A High-Performance, Inclusive Global Workforce6,165 employees worldwide, with 58% female representation and nearly 50% women in leadership rolesContinued investment in career development, training, and competitive benefits to attract and retain top biotech talentRecognized as a Global Talent Magnet Employer by LinkedIn4) Preserving Environment Backed by ScienceDecarbonization targets officially validated by the Science Based Targets initiative, aligning with a 1.5°C pathway and net-zero ambition by 2050Uninterrupted energy efficiency, renewable energy adoption, & process optimizationSystematic climate risk assessment embedded into enterprise risk management5) Community Impact Through Perpetual ActionOver 1,400 global volunteer hours contributed across environmental protection, healthcare, education, and community initiativesContinued collaboration with global partners to accelerate therapeutic innovation and expand patient accessGLOBAL RECOGNITION REINFORCING CREDIBILITY AND MOMENTUMGenScript’s ESG performance continues to earn top-tier international recognition, validating its disciplined, measurable, and transparent approach:MSCI ESG Rating: AAEcoVadis: Silver MedalSustainalytics: Low RiskInclusion in the S&P Global Sustainability Yearbook 2026Member of the FTSE4Good Index SeriesThese recognitions position GenScript among the leading responsible players in the global life sciences and biotech services sector.SUPPORTING SUSTAINABLE GROWTH IN BIOTECHNOLOGYThe 2025 ESG Report underscores GenScript’s continued focus on aligning business growth with responsible practices, as the company expands its global presence and contributes to the evolution of a more resilient and accountable biotechnology sector.This combination of innovation + governance + trust is what differentiates GenScript; not just as a service provider, but as a strategic enabler of the future of biotechnology.Access the Full Report: The full 2025 ESG Report is available at:EN: https://www.genscript.com/gsfiles/esg/2025-ESG-Report.pdfAbout GenScript Biotech CorporationFounded in 2002 in New Jersey, GenScript Biotech Corporation (HKEX: 1548) accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop ground breaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners – from academic institutions to industry leaders – to co-create cutting-edge solutions that redefine service excellence.Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world’s Top 20 pharma companies. For More Information, Media Contacts:Melis InceerHead of Integrated Communications & ContentMelis.Inceer@genscript.comKate GrusichSenior Corporate Communications ManagerKatherina.Grusich@genscript.comPhoto – https://www.newsoutnow.com/wp-content/uploads/2026/04/GenScript_ESG_2025.jpgLogo – https://www.newsoutnow.com/wp-content/uploads/2026/04/GenScript_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/genscript-sets-new-benchmark-for-responsible-biotech-leadership-with-2025-esg-report-302741516.html
